LPTX - Leap Therapeutics stock surges on positive mid-stage DKN-01 data

Leap Therapeutics (LPTX) shares up more than 13% premarket after posting positive data from its Phase 2 clinical trial of DKN-01 as a monotherapy and in combination with paclitaxel in patients with advanced gynecological malignancies.The P204 study was a Phase 2 basket study evaluating DKN-01 as a monotherapy or in combination with paclitaxel in groups composed of epithelial endometrial cancer ((EEC)), epithelial ovarian cancer ((EOC)), or carcinosarcoma ((MMMT)) patients.The primary endpoint of the study was overall response rate ((ORR)), and secondary endpoints include disease control rate ((DCR)) and progression-free survival ((PFS)).DKN-01 showed objective responses, including a monotherapy complete response continuing for over 2 and a half years, and durable tumor reductions as a single agent and in combination with paclitaxel in the advanced gynecologic cancer patients treated in the study.The activity of DKN-01 in the study was comparable to the monotherapy data from other widely-used immuno-oncology or targeted therapies.In the group of

For further details see:

Leap Therapeutics stock surges on positive mid-stage DKN-01 data